Patents by Inventor Yuichiro Tabunoki
Yuichiro Tabunoki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220162206Abstract: To provide a novel compound or a salt thereof or a solvate thereof, having a CSF-1R inhibitory activity and exhibiting antitumor effect. An azaindole derivative of formula (I): wherein A represents a C6-10 aryl ring, an aromatic heterocycle, or an unsaturated heterocycle, and A optionally has one substituent or more same or different substituents; and R represents a C1-3 alkyl group or a saturated heterocyclic group, or a salt thereof or a solvate thereof.Type: ApplicationFiled: March 30, 2020Publication date: May 26, 2022Applicant: KOWA COMPANY, LTD.Inventors: Gen WATANABE, Toshiharu MORIMOTO, Akira IWATA, Hirotaka SASAKI, Takahisa OGAMINO, Kosuke USUDA, Ayumu OKUDA, Hiroyuki ISHIWATA, Yuichiro TABUNOKI, Keigo NISHII
-
Patent number: 8575153Abstract: To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjögren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.Type: GrantFiled: November 27, 2009Date of Patent: November 5, 2013Assignee: Kowa Company, Ltd.Inventors: Takahiro Kitamura, Hajime Yamada, Shunji Takemura, Masanori Ashikawa, Tetsuya Ishikawa, Yoshiharu Miyake, Akiyasu Kouketsu, Seiichi Sato, Hiroyuki Ishiwata, Yuichiro Tabunoki, Manabu Shibasaki, Takatoshi Ozawa, Ryota Shigemi, Takeshi Doi, Masahiro Tamura
-
Publication number: 20110237590Abstract: To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjögren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.Type: ApplicationFiled: November 27, 2009Publication date: September 29, 2011Inventors: Takahiro Kitamura, Hajime Yamada, Shunji Takemura, Masanori Ashikawa, Tetsuya Ishikawa, Yoshiharu Miyake, Akiyasu Kouketsu, Seiichi Sato, Hiroyuki Ishiwata, Yuichiro Tabunoki, Manabu Shibasaki, Takatoshi Ozawa, Ryota Shigemi, Takeshi Doi, Masahiro Tamura
-
Publication number: 20100234407Abstract: The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory or inhibitory effect; as well as a diagnostic kit for a myeloma tumor, characterized by including a reagent for measuring blood osteopontin level, and a diagnostic method.Type: ApplicationFiled: January 4, 2010Publication date: September 16, 2010Applicant: KOWA CO., LTD.Inventors: Yukihiko Saeki, Hideyuki Kobayashi, Yuichiro Tabunoki
-
Patent number: 7745154Abstract: The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory or inhibitory effect; as well as a diagnostic kit for a myeloma tumor, characterized by including a reagent for measuring blood osteopontin level, and a diagnostic method.Type: GrantFiled: March 19, 2003Date of Patent: June 29, 2010Assignee: Kowa Co., Ltd.Inventors: Yukihiko Saeki, Hideyuki Kobayashi, Yuichiro Tabunoki
-
Publication number: 20100120732Abstract: Provided is an agent for prevention and/or treatment of systemic lupus erythematosus, which comprises, in combination, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazine-3-one or a solvate thereof and a corticosteroid. The pharmaceutical agent of the present invention is orally administrable, has fewer adverse effects, exhibits an excellent effect of suppressing the symptoms associated with SLE, and thus is useful for prevention and treatment of SLE.Type: ApplicationFiled: March 7, 2008Publication date: May 13, 2010Applicant: KOWA CO., LTD.Inventor: Yuichiro Tabunoki
-
Publication number: 20100075972Abstract: To provide a preventive and/or therapeutic drug for multiple sclerosis, which has high efficacy against multiple sclerosis, which exhibits excellent safety, and which can be orally administered. The invention provides a preventive and/or therapeutic drug for multiple sclerosis, the drug containing, as an active ingredient, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one or a solvate thereof.Type: ApplicationFiled: January 28, 2008Publication date: March 25, 2010Applicant: Kowa Co., Ltd.Inventors: Masaki Yamabi, Yuichiro Tabunoki, Toshiyuki Edano
-
Publication number: 20090281106Abstract: The present invention provides a prophylactic and/or therapeutic agent for rheumatoid arthritis comprising 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and leflunomide in combination. The prophylactic and/or therapeutic agent of the present invention can be administered orally, exhibits an excellent arthritis suppressive effect with fewer side effects, and is therefore useful for the prophylaxis and/or treatment of rheumatoid arthritis.Type: ApplicationFiled: August 30, 2006Publication date: November 12, 2009Applicant: Kowa Co., LtdInventors: Yuichiro Tabunoki, Tomoyuki Koshi
-
Publication number: 20090203701Abstract: A medicament having excellent therapeutic and prophylactic effects on rheumatoid arthritis is provided. A prophylactic and/or therapeutic agent for rheumatoid arthritis, comprising 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and an HMG-CoA reductase inhibitor in combination.Type: ApplicationFiled: June 27, 2007Publication date: August 13, 2009Applicant: KOWA CO., LTDInventor: Yuichiro Tabunoki
-
Publication number: 20090131443Abstract: The invention provides a method for the prevention and/or treatment of rheumatoid arthritis, characterized in that the method comprises administering an IL-1? inhibitor and a calcineurin inhibitor, and a preventive and/or therapeutic medicine for rheumatoid arthritis including an IL-1? inhibitor and a calcineurin inhibitor in combination. According to the invention, there can be provided a medicine and method for treating rheumatoid arthritis which exhibits suppressed side effects and excellent potency for suppression of arthritis.Type: ApplicationFiled: October 27, 2006Publication date: May 21, 2009Applicant: Kowa Co., Ltd.Inventors: Yuichiro Tabunoki, Tomoyuki Koshi
-
Publication number: 20090042901Abstract: The present invention relates to an agent for the prevention/therapy of a disease caused by keratinocyte growth, which comprises, as an active ingredient, a compound represented by General Formula (1): wherein A represents a group selected from groups of the following formulas: X represents CH or N; Y represents CH2 or C?O; Z represents CH or N; R1 represents an alkoxy group; R2 and R3 each independently represent an alkyl group; R4 represents an alkyl group, and a group of the following formula: R5 each independently represent an alkoxy group or an alkylthio group; m represents an integer from 1 to 3; n represents an integer of 1 or 2; and o represents an integer of 1 or 2, or a salt thereof, or a solvate of the compound or the salt.Type: ApplicationFiled: February 1, 2006Publication date: February 12, 2009Applicant: KOWA CO., LTD.Inventors: Toshiyuki Edano, Yuichiro Tabunoki, Tomoyuki Koshi
-
Publication number: 20090018121Abstract: The present invention relates to a preventive and/or therapeutic agent for rheumatoid arthritis. The present invention provides a preventive and/or therapeutic agent for rheumatoid arthritis containing 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and a COX2 inhibitor.Type: ApplicationFiled: March 28, 2006Publication date: January 15, 2009Applicant: Kowa Co., Ltd.Inventors: Yuichiro Tabunoki, Tomoyuki Koshi
-
Publication number: 20070270431Abstract: The present invention relates to a preventive and/or therapeutic medicine for rheumatoid arthritis containing 2-benzyl-5-(4-chlorophenyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and methotrexate. The medicine of the present invention can be administered orally and exhibits suppressed side effects and excellent potency for suppression of arthritis.Type: ApplicationFiled: September 29, 2005Publication date: November 22, 2007Applicant: Kowa Co., Ltd.Inventors: Yuichiro Tabunoki, Tomoyuki Koshi
-
Publication number: 20070142281Abstract: The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory or inhibitory effect; as well as a diagnostic kit for a myeloma tumor, characterized by including a reagent for measuring blood osteopontin level, and a diagnostic method.Type: ApplicationFiled: August 11, 2006Publication date: June 21, 2007Applicant: KOWA CO., LTD.Inventors: Yukihiko Saeki, Hideyuki Kobayashi, Yuichiro Tabunoki
-
Publication number: 20070021418Abstract: This invention relates to a method of inhibiting OPN production, which comprises administering an effective amount of a pyridazine derivative represented by the following formula (I) or a salt thereof: wherein: R1 means a substituted or unsubstituted phenyl or pyridyl group; R2 means a substituted phenyl group; R3 means a hydrogen atom or a substituted or unsubstituted phenyl or pyridyl group; A means a single bond, a C1-6 linear or branched alkylene group, or a C2-9 linear or branched alkenylene group; and X means an oxygen atom or a sulfur atom.Type: ApplicationFiled: July 29, 2004Publication date: January 25, 2007Applicant: Kowa Co., LTD.Inventors: Yukihiko Saeki, Yuichiro Tabunoki, Tomoyuki Koshi
-
Publication number: 20050250162Abstract: The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory or inhibitory effect; as well as a diagnostic kit for a myeloma tumor, characterized by including a reagent for measuring blood osteopontin level, and a diagnostic method.Type: ApplicationFiled: March 19, 2003Publication date: November 10, 2005Applicant: KOWA CO., LTD.Inventors: Yukihiko Saeki, Hideyuki Kobayashi, Yuichiro Tabunoki